Lupin Latest Updates

Lupin has recently launched Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the U.S. market (July 16, 2025), a generic equivalent to Bausch & Lomb's Lotemax®. This is for the treatment of steroid-responsive inflammatory eye conditions. Earlier this month, on July 4, 2025, they also launched Ipratropium Bromide Nasal Solution (0.03% and 0.06%) in the U.S. In terms of collaborations, Lupin and Zentiva Group entered a license and supply agreement on July 9, 2025, for the global commercialization of Lupin's biosimilar Certolizumab Pegol. Lupin will handle development, manufacturing, and supply, with commercialization split between Lupin (US and Canada) and Zentiva (Rest of World). Additionally, on June 16, 2025, Lupin signed a license and supply agreement with Sino Universal Pharmaceuticals for the commercialization of Tiotropium Dry Powder Inhaler (DPI) in China. Lupin's Board has recommended a ₹12 final dividend per equity share for the financial year ended March 31, 2025. The record date for this dividend is set for Friday, July 25, 2025, with the Annual General Meeting (AGM) scheduled for Monday, August 11, 2025. For the full financial year 2025, Lupin reported consolidated sales of ₹2,21,921 million, an increase of 12.9% year-on-year. The company's Profit After Tax (PAT) surged by 70.8% to ₹33,063 million for FY25. North America sales for FY2025 were ₹83,950 million, up 15.9% year-on-year.